Characterization of cytochrome P450s mediating ipriflavone metabolism in human liver microsomes

References

• Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica 1995; 25: 261–270
   PubMed Web of Science ®Google Scholar
• Bassleer CT, Franchimont PP, Henrotin YE, Franchimont NM, Geenen VG, Reginster JY. Effects of ipriflavone and its metabolites on human articular chondrocytes cultivated in clusters. Osteoarthritis Cartilage 1996; 4: 1–8
   PubMed Web of Science ®Google Scholar
• Benvenuti S, Tanini A, Frediani U, Bianchi S, Masi L, Casano R, Bufalino L, Serio M, Brandi ML. Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line. Journal of Bone and Mineral Research 1991; 6: 987–996
   PubMed Web of Science ®Google Scholar
• Cheng SL, Zhang SF, Nelson TL, Warlow PM, Civitelli R. Stimulation of human osteoblast differentiation and function by ipriflavone and its metabolites. Calcified Tissue International 1994; 55: 356–362
   PubMed Web of Science ®Google Scholar
• Chung HJ, Choi YH, Kim SH, Lee MG. Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous ipriflavone in rats. Journal of Pharmacy and Pharmacology 2006; 58: 449–457
   PubMedGoogle Scholar
• Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metabolism and Disposition 2001; 29: 23–29
   PubMed Web of Science ®Google Scholar
• Ferenc L, Istvan S. Metabolism of ipriflavone. Acta Pharmaceutica Hungarica 1995; 65: 215–218
   PubMedGoogle Scholar
• Gibson GG, Plant NJ, Swales KE, Ayrton A, El-Sankary W. Receptor-dependent transcriptional activation of CYP3A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 2002; 32: 165–206
   PubMed Web of Science ®Google Scholar
• Giossi M, Caruso P, Civelli M, Bongrani S. Inhibition of parathyroid hormone-stimulated resorption in cultured fetal rat long bones by the main metabolites of ipriflavone. Calcified Tissue International 1996; 58: 419–422
   PubMed Web of Science ®Google Scholar
• Goldstein JA. Clinical relevance of genetic polymorphism in the human CYP2C subfamily. British Journal of Clinical Pharmacology 2001; 52: 349–355
   PubMed Web of Science ®Google Scholar
• Head KA. Ipriflavone: An important bone-building isoflavone. Alternative Medicine Review 1999; 4: 10–22
   PubMedGoogle Scholar
• Ji HY, Lee HW, Kim HH, Paek IB, Moon Y, Kim SH, Lee MG, Lee HS. Simultaneous determination of ipriflavone and its main metabolites M1 and M5 in human plasma by liquid chromatography with tandem mass spectrometry. Analytical Letters 2005; 38: 99–110
   Web of Science ®Google Scholar
• Kim SH, Lee MG. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats. Hepatic and intestinal first-pass effects. Life Sciences 2002; 70: 1299–1315
   PubMed Web of Science ®Google Scholar
• Kim SH, Lee JS, Lee MG. Pharmacokinetics and tissue distribution of ipriflavone, an isoflavone derivative, after intravenous administration to rabbits. Biopharmaceutics and Drug Disposition 2000; 21: 147–156
   PubMedGoogle Scholar
• Luo G, Guenthner T, Gan LS, Humphreys WG. CYP3A4 induction by xenobiotics: Biochemistry, experimental methods and impact on drug discovery and development. Current Drug Metabolism 2004; 5: 483–505
   PubMed Web of Science ®Google Scholar
• Miners JO, Birkett DJ. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. British Journal of Clinical Pharmacology 1998; 45: 525–538
   PubMed Web of Science ®Google Scholar
• Miners JO, McKinnon RA. CYP1A. Metabolic drug interactions, RH Levy, KE Thummel, WF Trager, PD Hansten, M Eichelbaum. Lippincott, Williams & Wilkins, Philadelphia 2000
   Google Scholar
• Monostory K, Vereczkey L. Interaction of theophylline and ipriflavone at the cytochrome P450 level. European Journal of Drug Metabolism and Pharmacokinetics 1995; 20: 43–47
   PubMedGoogle Scholar
• Monostory K, Vereczkey L. Effect of ipriflavone and its main metabolites on theophylline biotransformation. European Journal of Drug Metabolism and Pharmacokinetics 1996; 21: 61–66
   PubMedGoogle Scholar
• Monostory K, Vereczkey L, Levai F, Szatmari I. Ipriflavone as an inhibitor of human cytochrome P450 enzymes. British Journal of Pharmacology 1998; 123: 605–610
   PubMed Web of Science ®Google Scholar
• Newton DJ, Wang RW, Lu AY. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition 1995; 23: 154–158
   PubMed Web of Science ®Google Scholar
• Rae JM, Soukhova NV, Flockhart DA, Desta Z. Triethylenethiophosphamide is a specific inhibitor of cytochrome P-450 2B6: Implications for cyclophosphamide metabolism. Drug Metabolism and Disposition 2002; 30: 525–530
   PubMed Web of Science ®Google Scholar
• Reginster JY. Ipriflavone: Pharmacological properties and usefulness in postmenopausal osteoporosis. Bone Mineral 1993; 23: 223–232
   PubMedGoogle Scholar
• Rohatagi S, Barrett JS. Integrated pharmacokinetic and metabolic modeling of ipriflavone and metabolites after oral administration. American Journal of Therapeutics 1997; 4: 189–198
   PubMedGoogle Scholar
• Rohatagi S, Barrett JS, Sawyers W, Yu K, Morales RJ. Pharmacokinetics of ipriflavone and metabolites after oral administration of a corn-oil suspension relative to the Osteofix tablet. American Journal of Therapeutics 1997; 4: 229–238
   PubMedGoogle Scholar
• Ronelli I, Acerbi D, Ventura P. Steady-state pharmacokinetics of ipriflavone and its metabolites in patients with renal failure. International Journal of Clinical Pharmaceutical Research 1991; 11: 183–192
   PubMedGoogle Scholar
• Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de la Torre R, Davies DS. Furafylline is a potent and selective inhibitor of cytochrme P450IA2 in man. British Journal of Clinical Pharmacology 1990; 29: 651–663
   PubMed Web of Science ®Google Scholar
• Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, Goldstein JA. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 1993; 3: 239–249
   PubMedGoogle Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Suzuki H, Kneller MB, Haining RL, Trager WF, Rettie AE. (+)-N-3-Benzyl-Nirvanol and (−)-N-3-benzyl-phenobarbital: New potent and selective in vitro inhibitors of CYP2C19. Drug Metabolism and Disposition 2002; 30: 235–239
   PubMed Web of Science ®Google Scholar
• Takahashi J, Kawakatsu K, Wakayama T, Sawaoka H. Elevation of serum theophylline levels by ipriflavone in a patient with chronic obstructive pulmonary disease. European Journal of Clinical Pharmacology 1992; 43: 207–208
   PubMedGoogle Scholar
• Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Relative quantities of catalytically active CYP2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach. Journal of Pharmaceutical Sciences 1998; 87: 845–853
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitor. Drug Metabolism and Disposition 2003; 31: 343
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS, Gaman EA, Gleeson JPR, Proctor WR. Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metabolism and Disposition 2005; 33: 413–418
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P-450 IIIA4 (HLp3). Molecular Pharmacology 1990; 38: 207–213
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Thummel KE. CYP3A. Metabolic drug interactions, RH Levy, KE Thummel, WF Trager, PD Hansten, M Eichelbaum. Lippincott, Williams & Wilkins, Philadelpia 2000
   Google Scholar
• Yoshida K, Tsukamoto T, Torii H, Doi T, Naeshiro I, Uemura I, Tanayama S. Metabolism of ipriflavone (TC-80) in rats. Radioisotopes 1985; 34: 612–617
   PubMedGoogle Scholar
• Yun CH, Shimada T, Guengerich FP. Purification and characterization of human liver microsomal cytochrome P450 2A6. Molecular Pharmacology 1991; 40: 679–685
   PubMed Web of Science ®Google Scholar